Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact.
CTLA-4
PD-L1
breast cancer
circulating tumor cells
detyrosinated α-tubulin (GLU)
luminal
triple negative breast cancer
vimentin (VIM)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Mar 2023
25 Mar 2023
Historique:
received:
02
03
2023
revised:
19
03
2023
accepted:
23
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. There are few targeted therapies for these patients, leading to an unmet need for new biomarkers. The present study aimed to investigate the expression of PD-L1, CTLA-4, GLU, and VIM in CTCs of TNBC patients. Ninety-five patients were enrolled in this study: sixty-four TNBC and thirty-one luminal. Of these patients, 60 were in the early stage, while 35 had metastatic disease. Protein expression was identified by immunofluorescence staining experiments and VyCAP analysis. All the examined proteins were upregulated in TNBC patients. The expression of the GLU
Identifiants
pubmed: 37046635
pii: cancers15071974
doi: 10.3390/cancers15071974
pmc: PMC10093450
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33947159
Cell Syst. 2019 Aug 28;9(2):109-127
pubmed: 31465728
J Pers Med. 2022 Jan 25;12(2):
pubmed: 35207643
Cancer Lett. 2010 Feb 1;288(1):99-106
pubmed: 19619935
Arch Immunol Ther Exp (Warsz). 2021 Jun 20;69(1):16
pubmed: 34148159
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Cancer. 2020 Sep 9;11(21):6365-6375
pubmed: 33033520
Cancer Discov. 2016 Jun;6(6):OF7
pubmed: 27091855
Clin Exp Med. 2006 Jun;6(2):89-93
pubmed: 16820997
Mol Cancer Res. 2013 Oct;11(10):1248-57
pubmed: 23744981
Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121
pubmed: 29383038
Breast Cancer Res. 2011 Jun 10;13(3):R59
pubmed: 21663619
Curr Opin Immunol. 2015 Apr;33:23-35
pubmed: 25621841
Front Chem. 2021 Nov 08;9:766107
pubmed: 34858943
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Breast Cancer Res. 2013;15(5):R83
pubmed: 24028602
Mol Oncol. 2015 Nov;9(9):1773-82
pubmed: 26093818
Oncotarget. 2015 Oct 20;6(32):33972-81
pubmed: 26378017
J Cancer Res Clin Oncol. 2013 May;139(5):739-46
pubmed: 23354842
Mol Med. 2007 Jan-Feb;13(1-2):79-88
pubmed: 17515959
J Pers Med. 2021 Aug 19;11(8):
pubmed: 34442452
Expert Rev Mol Diagn. 2021 Oct;21(10):1037-1048
pubmed: 34328384
Breast Cancer Res Treat. 2014 Jul;146(1):15-24
pubmed: 24842267
J Cancer. 2016 Apr 10;7(7):784-93
pubmed: 27162536
Clin Cancer Res. 2004 Dec 15;10(24):8152-62
pubmed: 15623589
J Exp Clin Cancer Res. 2021 Jun 4;40(1):184
pubmed: 34088360
Breast Cancer Res Treat. 2012 May;133(1):75-87
pubmed: 21818590
Eur J Med Chem. 2021 Mar 5;213:113058
pubmed: 33280898
Clin Chem. 2021 Nov 01;67(11):1503-1512
pubmed: 34355741
Exp Cell Res. 2007 Apr 15;313(7):1326-36
pubmed: 17359970
Oncotarget. 2017 Jan 17;8(3):5309-5322
pubmed: 28029660
BMC Cancer. 2017 May 16;17(1):333
pubmed: 28511705
J Clin Oncol. 2002 Aug 15;20(16):3404-12
pubmed: 12177100
Cancer Immunol Immunother. 2021 Mar;70(3):607-617
pubmed: 33015734
Med Hypotheses. 2016 Aug;93:138-9
pubmed: 27372873
Mol Ther. 2021 Jun 2;29(6):1958-1969
pubmed: 33932597
PLoS One. 2017 Aug 10;12(8):e0182692
pubmed: 28796808
Oncologist. 2016 May;21(5):634-42
pubmed: 26984449
Ann Oncol. 2017 Aug 01;28(8):1923-1933
pubmed: 28838214
Eur J Med Chem. 2018 Jan 1;143:1277-1300
pubmed: 29126724
J Clin Lab Anal. 2006;20(3):105-8
pubmed: 16721836
Discov Med. 2016 Feb;21(114):125-33
pubmed: 27011048
Cancer Drug Resist. 2021;4(3):517-542
pubmed: 34888495
Breast Cancer Res. 2018 Jul 5;20(1):67
pubmed: 29976237
Mol Cancer Ther. 2013 Sep;12(9):1886-95
pubmed: 23778153
J Natl Cancer Inst. 2009 Jan 7;101(1):61-6
pubmed: 19116383
Cancer Res. 2008 Jul 15;68(14):5678-88
pubmed: 18632620
Acta Pharmacol Sin. 2021 Jan;42(1):1-9
pubmed: 32152439
Mol Clin Oncol. 2020 Jun;12(6):565-573
pubmed: 32337039
Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18115-20
pubmed: 20921380
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Cancer Res. 2001 Jul 1;61(13):5024-7
pubmed: 11431336
Breast Cancer Res. 2008;10(5):R80
pubmed: 18822183
Clin Chem. 2020 Aug 1;66(8):1093-1101
pubmed: 32712650